Peer-influenced content. Sources you trust. No registration required. This is HCN.
JAMA Network
The only effective ways to treat TEC are to stop, delay, or modify your patients’ chemotherapy dose. Supportive medications, such as topical keratolytics, wound care, and high-potency topical corticosteroids, respond differently. These medications cause a 2- to 4-week recovery period following the interruption of chemotherapy, which is a somewhat gradual improvement.
Clinical Pharmacology January 9th 2023
Psych Congress Network
Eighty-eight children ages 6 through 12 were randomized to daily pine bark extract, methylphenidate, or placebo for 10 weeks. Total ADHD-Rating Scales scores decreased 29% with pine bark extract, 45% with methylphenidate, and 5% with placebo. Hyperactivity/impulsivity decreased 34% with pine bark extract and 36% with methylphenidate and increased 1% with placebo. Inattention decreased 25% with pine bark extract, 52% with methylphenidate, 9% with placebo. Adverse events were reported 5 times more frequently with methylphenidate than with pine bark.
Neurology November 14th 2022
Psychiatrist.com
Bupropion inhibits cytochrome P450 2D6,5 which is the enzyme that converts venlafaxine into an active metabolite, desvenlafaxine. When CYP2D6 is inhibited, venlafaxine levels rise at the expense of desvenlafaxine. Because the renal excretion of venlafaxine is small, the consequence is increased dose-dependent venlafaxine-related adverse effects.
Clinical Pharmacology October 27th 2022
In this meta-analysis including 340 patients across six clinical trials, ECT was more effective than ketamine in treating depression. There were no identified differences between the groups in terms of cognition, memory, or serious adverse events.
Neurology October 25th 2022
Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment and the majority are mild or moderate in severity.
Psychiatry October 7th 2022
MDLinx
Data on more than 200,000 individuals revealed that non-SSRI antidepressants were associated with a two-fold increased risk of coronary heart disease, cardiovascular mortality, and all-cause mortality at ten years. There was also evidence that SSRIs were associated with lower rates of hypertension and diabetes.
Cardiology October 7th 2022